rs5253
Variant summary
Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1
The NM_000085.5(CLCNKB):āc.1685T>Cā(p.Met562Thr) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.96 in 1,613,870 control chromosomes in the GnomAD database, including 747,019 homozygotes. In-silico tool predicts a benign outcome for this variant. 14/19 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Benign (ā ā ).
Frequency
Consequence
NM_000085.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -20 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CLCNKB | NM_000085.5 | c.1685T>C | p.Met562Thr | missense_variant | 16/20 | ENST00000375679.9 | NP_000076.2 | |
CLCNKB | NM_001165945.2 | c.1178T>C | p.Met393Thr | missense_variant | 9/13 | NP_001159417.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CLCNKB | ENST00000375679.9 | c.1685T>C | p.Met562Thr | missense_variant | 16/20 | 1 | NM_000085.5 | ENSP00000364831.5 |
Frequencies
GnomAD3 genomes AF: 0.888 AC: 134991AN: 152028Hom.: 61122 Cov.: 32
GnomAD3 exomes AF: 0.935 AC: 234686AN: 251092Hom.: 110523 AF XY: 0.941 AC XY: 127782AN XY: 135846
GnomAD4 exome AF: 0.967 AC: 1413473AN: 1461724Hom.: 685876 Cov.: 69 AF XY: 0.967 AC XY: 703266AN XY: 727186
GnomAD4 genome AF: 0.888 AC: 135058AN: 152146Hom.: 61143 Cov.: 32 AF XY: 0.885 AC XY: 65849AN XY: 74384
ClinVar
Submissions by phenotype
not specified Benign:4
Benign, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Mar 21, 2016 | p.Met562Thr in exon 16 of CLCNKB: This variant is not expected to have clinical significance because it has been identified in 98.02% (65150/66466) of European chromosomes by the Exome Aggregation Consortium (ExAC, http://exac.broadinstitut e.org; dbSNP rs5253). - |
Benign, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
Benign, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Benign, criteria provided, single submitter | clinical testing | Athena Diagnostics | Jul 26, 2017 | - - |
not provided Benign:3
Benign, criteria provided, single submitter | clinical testing | GeneDx | Nov 10, 2018 | - - |
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 01, 2024 | - - |
Benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Bartter disease type 3 Benign:1
Benign, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Jul 22, 2021 | - - |
Bartter disease type 4B Benign:1
Benign, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Jul 22, 2021 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at